Biotech

All Articles

FDA locations Kezar lupus trial in hold observing 4 individual fatalities

.The FDA has positioned Kezar Life Sciences' lupus test on hold after the biotech flagged four death...

Phase 3 Historian Rock trial hits SMA objective, delivering stock up 200%

.A period 3 trial of Historian Stone's back muscle degeneration (SMA) prospect has hit its key endpo...

CAMP 4 is actually newest to eye IPO, while Upstream spells out $182M planning

.RNA biotech CAMP4 Therapies has actually defined plans for a $67 million IPO, along with inflammati...

Galecto acquires leukemia medicine, loses bone tissue cancer resource in pivot

.A year after the failure of an idiopathic pulmonary fibrosis applicant delivered Galecto on a look ...

Judo tosses down $100M to knock out renal health condition

.Taking the mat is actually Judo Biography, an ambitious biotech equipped along with $100 thousand t...

AstraZeneca spends CSPC $100M for preclinical heart problem medication

.AstraZeneca has paid off CSPC Drug Team $100 million for a preclinical heart disease medicine. The ...

Zephyrm seeks Hong Kong IPO to money period 3 cell treatment trials

.Zephyrm Bioscience is actually gusting toward the Hong Kong stock exchange, filing (PDF) for an IPO...

Frazier Lifestyle Sciences gathers $630M for little, mid-cap biotechs

.Frazier Lifespan Sciences has sourced a further $630 thousand for its fund concentrated on little a...

GigaGen garners around $135M BARDA bucks to beat botulism

.Antibody fan GigaGen, a subsidiary of Spanish biopharma Grifols, is actually ramping up its technic...

GPCR company Septerna files for IPO on strength of preclinical information

.Septerna is about to determine how a biotech without "any type of purposeful medical data" meals in...